{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:27:02Z","timestamp":1792888022227,"version":"4.5.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Despite rising hepatitis C virus (HCV) incidence in pregnant people, studies demonstrate that fewer than 50% of perinatally exposed infants receive HCV testing. Few studies report treatment of infected infants or factors affecting testing.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To identify birthing parent and child factors associated with appropriate HCV testing for perinatally exposed infants and characterize HCV care for children with HCV.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study included records on testing, care, and treatment for Massachusetts children perinatally exposed to HCV between 2014 and 2021 from a statewide health database linking statewide vital statistics, infectious disease surveillance data, substance use treatment, and insurance claims data. Data were analyzed from April 2023 to June 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Linkage to a birthing parent with a confirmed (RNA positive) or probable (antibody positive; no RNA testing) HCV case reported to the Massachusetts Department of Public Health.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Guideline-appropriate HCV antibody or RNA testing and HCV treatment were the main outcomes. Multivariable logistic regressions were used to analyze factors associated with guideline-concordant HCV testing.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Between 2014 and 2021, 4548 children were born (between 0.7% and 1.3% of yearly births) in Massachusetts to 3693 birthing parents with probable or confirmed HCV; among 4103 children who were aged 2 years or older by study end (2103 male [51.3%]; 289 Black non-Hispanic [7.0%], 575 Hispanic [14.0%], 3069 White non-Hispanic [74.8%]; 3185 [77.6%] with public insurance at delivery), 41.9% completed appropriate perinatal HCV exposure testing. HCV was diagnosed in 40 (2.5%) of those tested; between 1 and 10 of 38 treatment-eligible children were treated by 2022 (number suppressed due to value between 1 and 10). Appropriate testing rates decreased over time and were lowest for those born in 2020 (32.3%; 95% CI, 28.9%-35.7%). A medical claim for the birthing parent\u2019s HCV within 30 days of delivery (adjusted odds ratio [aOR], 5.40; 95% CI, 4.19-6.96), medication for opioid use disorder treatment during pregnancy (aOR, 1.29; 95% CI, 1.09-1.51), and factors correlated with HCV risk were associated with significantly higher odds of appropriate testing; non-Hispanic Black race (aOR, 0.65; 95% CI, 0.45-0.94) and private insurance (aOR, 0.76; 95% CI, 0.62-0.93) were associated with lower appropriate testing odds.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of perinatally exposed infants, HCV testing decreased over time, and few were treated. Communication and recognition of the birthing parent\u2019s HCV risk or diagnosis were associated with greater odds of testing completion; these modifiable factors could be addressed to improve equitable HCV testing and care.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.0743","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:30:21Z","timestamp":1776439821000},"page":"e260743","source":"Crossref","is-referenced-by-count":2,"title":["Hepatitis C Virus Testing in Perinatally Exposed Children"],"prefix":"10.1001","volume":"9","author":[{"given":"Rachel L.","family":"Epstein","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts"},{"name":"Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Munroe","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Erdman","sequence":"additional","affiliation":[{"name":"Office of Population Health, Massachusetts Department of Public Health, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Bettano","sequence":"additional","affiliation":[{"name":"Office of Population Health, Massachusetts Department of Public Health, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan R.","family":"Curtis","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"White","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisha M.","family":"Wachman","sequence":"additional","affiliation":[{"name":"Section of Newborn Medicine, Department of Pediatrics, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Osinski","sequence":"additional","affiliation":[{"name":"Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Y.","family":"Walley","sequence":"additional","affiliation":[{"name":"Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts"},{"name":"Bureau of Substance Addiction Services, Massachusetts Department of Public Health, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.","family":"Linas","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts"},{"name":"Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"4","key":"zoi260050r1","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/AOG.0000000000005119","article-title":"Deliveries among patients with maternal hepatitis C virus infection in the United States, 2000-2019.","volume":"141","author":"Arditi","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"3","key":"zoi260050r2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/AOG.0000000000005306","article-title":"Risk factors for perinatal transmission of hepatitis C virus.","volume":"142","author":"Prasad","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"4","key":"zoi260050r3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7204a1","article-title":"CDC recommendations for hepatitis C testing among perinatally exposed infants and children\u2014United States, 2023.","volume":"72","author":"Panagiotakopoulos","year":"2023","journal-title":"MMWR Recomm Rep"},{"issue":"2","key":"zoi260050r4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","article-title":"CDC recommendations for hepatitis C screening among adults\u2014United States, 2020.","volume":"69","author":"Schillie","year":"2020","journal-title":"MMWR Recomm Rep"},{"issue":"2","key":"zoi260050r5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.clp.2021.03.007","article-title":"Hepatitis C virus in neonates and infants.","volume":"48","author":"Epstein","year":"2021","journal-title":"Clin Perinatol"},{"key":"zoi260050r10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jpeds.2018.07.006","article-title":"Perinatal transmission of hepatitis C virus: defining the cascade of care.","volume":"203","author":"Epstein","year":"2018","journal-title":"J Pediatr"},{"issue":"1","key":"zoi260050r11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3233\/NPM-190264","article-title":"Maternal risk factors associated with inadequate testing and loss to follow-up in infants with perinatal hepatitis C virus exposure.","volume":"14","author":"Bhardwaj","year":"2021","journal-title":"J Neonatal Perinatal Med"},{"issue":"6","key":"zoi260050r12","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-3273","article-title":"Hepatitis C virus screening among children exposed during pregnancy.","volume":"141","author":"Chappell","year":"2018","journal-title":"Pediatrics"},{"issue":"9","key":"zoi260050r13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/jpids\/piae066","article-title":"Pediatric hepatitis C screening by maternal hepatitis C infection status during pregnancy.","volume":"13","author":"DiNicola","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"3","key":"zoi260050r14","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-2482","article-title":"Hepatitis C testing among perinatally exposed infants.","volume":"145","author":"Lopata","year":"2020","journal-title":"Pediatrics"},{"key":"zoi260050r15","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.1093\/jpids\/piae082","article-title":"Racial and ethnic disparities in testing of hepatitis C virus-exposed children across the United States.","volume":"13","author":"Epstein","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"6","key":"zoi260050r16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-067260","article-title":"Inequities in hepatitis virus testing for perinatally exposed infants in Tennessee: 2018 to 2023.","volume":"154","author":"Thomas","year":"2024","journal-title":"Pediatrics"},{"issue":"1","key":"zoi260050r17","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-064745","article-title":"Factors associated with perinatal hepatitis C screening among exposed children: 2016-2020.","volume":"154","author":"Kuncio","year":"2024","journal-title":"Pediatrics"},{"issue":"6","key":"zoi260050r18","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-067261","article-title":"Hepatitis C virus testing among perinatally exposed children: 2018 to 2020.","volume":"154","author":"Woodworth","year":"2024","journal-title":"Pediatrics"},{"issue":"5","key":"zoi260050r20","doi-asserted-by":"publisher","DOI":"10.1056\/CAT.19.1118","article-title":"Using data to guide action in response to the public health crisis of opioid overdoses.","volume":"1","author":"Bharel","year":"2020","journal-title":"NEJM Catal"},{"key":"zoi260050r25","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.1093\/jpids\/piae078","article-title":"Adopting the 2023 CDC Early Testing for Perinatal Hepatitis C: call to action for pediatric primary care providers.","volume":"13","author":"Saleh","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"6","key":"zoi260050r26","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-068246","article-title":"A call to pediatricians: how can we improve HCV testing in perinatally exposed infants?","volume":"154","author":"Epstein","year":"2024","journal-title":"Pediatrics"},{"issue":"4","key":"zoi260050r27","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/INF.0000000000000129","article-title":"Interventions using electronic medical records improve follow up of infants born to hepatitis C virus infected mothers.","volume":"33","author":"Abughali","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"zoi260050r28","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-068565","article-title":"Disparities in linkage to care among children with hepatitis C virus in the United States.","volume":"155","author":"Curtis","year":"2025","journal-title":"Pediatrics"},{"issue":"5","key":"zoi260050r29","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piaf042","article-title":"Pediatric and adolescent hepatitis C care cascade and real-world treatment outcomes utilizing an integrated health system specialty pharmacy model.","volume":"14","author":"Carver","year":"2025","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"12","key":"zoi260050r30","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3748\/wjg.v27.i12.1117","article-title":"Cascade of care for children and adolescents with chronic hepatitis C.","volume":"27","author":"Rogers","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"3","key":"zoi260050r31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/cld.1028","article-title":"Working toward elimination of hepatitis C: the Kentucky Hepatitis Academic Mentorship Program.","volume":"16","author":"Cave","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"1","key":"zoi260050r32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/AOG.0000000000004822","article-title":"Hepatitis C virus testing during pregnancy after universal screening recommendations.","volume":"140","author":"Kaufman","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"15","key":"zoi260050r33","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1001\/jama.2024.28774","article-title":"Hepatitis C virus screening in pregnant and nonpregnant women after universal screening guidelines.","volume":"333","author":"Singh","year":"2025","journal-title":"JAMA"},{"key":"zoi260050r6","doi-asserted-by":"crossref","DOI":"10.1542\/9781610025225","volume-title":"Red Book: 2021\u20132024 Report of the Committee on Infectious Diseases","author":"Kimberlin","year":"2021","edition":"32nd ed"},{"key":"zoi260050r7","unstructured":"US Food and Drug Administration Office of the Commissioner. FDA approves first treatment for all genotypes of hepatitis C in pediatric patients. FDA news release. April 30, 2019. Accessed June 1, 2019. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-all-genotypes-hepatitis-c-pediatric-patients"},{"key":"zoi260050r8","unstructured":"US Food and Drug Administration Office of the Commissioner. FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks. FDA news release. March 24, 2020. Accessed September 22, 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-adults-and-children-all-genotypes-hepatitis-c-and-compensated-cirrhosis"},{"key":"zoi260050r9","unstructured":"Mavyret (glecaprevir and pibrentasvir) FDA approval history. Drugs.com webpage. Updated June 13, 2025. Accessed September 22, 2023. https:\/\/www.drugs.com\/history\/mavyret.html"},{"key":"zoi260050r19","unstructured":"US Department of Health and Human Services. Viral hepatitis national strategic plan for the United States: a roadmap to elimination (2021\u20132025). Reviewed February 4, 2024. Accessed July 29, 2021. https:\/\/www.hhs.gov\/hepatitis\/viral-hepatitis-national-strategic-plan\/index.html"},{"key":"zoi260050r21","unstructured":"Public Health Data warehouse (PHD) Technical Documentation. Mass.gov. Accessed January 19, 2025. https:\/\/www.mass.gov\/info-details\/public-health-data-warehouse-phd-technical-documentation"},{"key":"zoi260050r22","unstructured":"Centers for Disease Control and Prevention. Hepatitis C, chronic 2020 case definition. National Notifiable Diseases Surveillance System (NNDSS). April 16, 2021. Accessed April 14, 2024. https:\/\/ndc.services.cdc.gov\/case-definitions\/hepatitis-c-chronic-2020\/"},{"key":"zoi260050r23","unstructured":"Massachusetts Department of Public Health, Bureau of Infectious Disease and Laboratory Sciences. Hepatitis C virus infection 2017-2021 surveillance report. 2023. Accessed April 14, 2024. http:\/\/www.mass.gov\/eohhs\/gov\/departments\/dph\/programs\/id\/"},{"key":"zoi260050r24","unstructured":"New Jersey Department of Health. The Kotelchuck Index. Accessed October 14, 2025. https:\/\/www-doh.nj.gov\/doh-shad\/query\/Kotelchuck.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847874\/epstein_2026_oi_260050_1775848025.59442.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:30:26Z","timestamp":1776439826000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.0743","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]}}}